JP2025507308A - 化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法 - Google Patents

化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法 Download PDF

Info

Publication number
JP2025507308A
JP2025507308A JP2024546251A JP2024546251A JP2025507308A JP 2025507308 A JP2025507308 A JP 2025507308A JP 2024546251 A JP2024546251 A JP 2024546251A JP 2024546251 A JP2024546251 A JP 2024546251A JP 2025507308 A JP2025507308 A JP 2025507308A
Authority
JP
Japan
Prior art keywords
mmol
compound
mixture
pharma
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507308A5 (enExample
Inventor
ユー，ニンフイ
ロウ，ロンリャン
Original Assignee
キャンウェル バイオテック リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャンウェル バイオテック リミテッド filed Critical キャンウェル バイオテック リミテッド
Publication of JP2025507308A publication Critical patent/JP2025507308A/ja
Publication of JP2025507308A5 publication Critical patent/JP2025507308A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/40—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024546251A 2022-02-08 2023-02-03 化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法 Pending JP2025507308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/075427 2022-02-08
PCT/CN2022/075427 WO2023150899A1 (en) 2022-02-08 2022-02-08 Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
PCT/CN2023/074329 WO2023151513A1 (en) 2022-02-08 2023-02-03 Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2025507308A true JP2025507308A (ja) 2025-03-18
JP2025507308A5 JP2025507308A5 (enExample) 2026-02-09

Family

ID=87563330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546251A Pending JP2025507308A (ja) 2022-02-08 2023-02-03 化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法

Country Status (8)

Country Link
US (1) US20250082657A1 (enExample)
EP (1) EP4476226A1 (enExample)
JP (1) JP2025507308A (enExample)
CN (1) CN118946569A (enExample)
AU (1) AU2023217770A1 (enExample)
CA (1) CA3243247A1 (enExample)
IL (1) IL314835A (enExample)
WO (2) WO2023150899A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118515573B (zh) * 2024-07-19 2024-09-27 浙江省产品质量安全科学研究院 一种稳定同位素标记的氘代奥拉氟化合物的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350756B1 (en) * 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
CN1982313B (zh) * 2005-12-13 2010-12-01 深圳市天和医药科技开发有限公司 10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
US20160095939A1 (en) * 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
US9150585B2 (en) * 2012-11-13 2015-10-06 Fl Therapeutics Llc Analogs of camptothecin
CN103848840A (zh) * 2012-12-03 2014-06-11 中国人民解放军军事医学科学院毒物药物研究所 喜树碱衍生物及其医药用途
CN105315294B (zh) * 2014-06-26 2018-05-01 王杭祥 7-乙基-10-羟基喜树碱药物前体及其制备方法和应用
CN104447777B (zh) * 2014-11-26 2016-09-14 浙江大学 一种辣椒碱-喜树碱类抗癌药物偶联物及其制备方法和应用
CN106377528B (zh) * 2016-08-19 2019-05-31 湖北医药学院 一种羟基喜树碱戊二酸单酯的药物组合物
CN106588946B (zh) * 2017-01-25 2019-01-22 郑州大学 10-羟基喜树碱衍生物、合成方法及其应用
KR101990214B1 (ko) * 2017-12-12 2019-06-17 고려대학교 산학협력단 표적 특이적 항암 약물전구체
CN109675050A (zh) * 2018-12-27 2019-04-26 浙江工业大学 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用
CN110372766A (zh) * 2019-06-21 2019-10-25 广州中医药大学(广州中医药研究院) 喜树碱糖类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
WO2023151513A1 (en) 2023-08-17
US20250082657A1 (en) 2025-03-13
AU2023217770A1 (en) 2024-08-22
WO2023150899A1 (en) 2023-08-17
CN118946569A (zh) 2024-11-12
IL314835A (en) 2024-10-01
CA3243247A1 (en) 2023-08-17
EP4476226A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
KR102548191B1 (ko) 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용
EP4083038B1 (en) Pyridazinyl thiazolecarboxamide compound
TWI813666B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
JP2022174114A (ja) Ａｌｋタンパク質分解剤及びそれらの癌療法における使用
AU2025275335A1 (en) Novel small molecule inhibitors of TEAD transcription factors
CN115109078A (zh) 嘧啶并吡啶类抑制剂及其制备方法和应用
CN114409653A (zh) 一种桥环并嘧啶并环类化合物及其用途
CN110156813A (zh) 作为trk抑制剂的杂环化合物
JP7538803B2 (ja) イミダゾキノリンアミン誘導体、医薬組成物、その使用
CN110945000A (zh) 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
CN113698390B (zh) 用作ret激酶抑制剂的化合物及其应用
KR20250112279A (ko) 헤테로고리 화합물, 이의 제조 방법 및 용도
JP2025507308A (ja) 化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法
IL314070A (en) Macrocyclic compounds and use as kinase inhibitors
CN117510504A (zh) 蛋白激酶降解剂、药物及应用
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
HK40118706A (zh) 化疗药物和组织结合小分子的缀合物、其组合物和方法
WO2022156449A1 (zh) 新型苯并氮杂䓬类化合物、组合物及其用途
US20240208942A1 (en) Metap-2 inhibitors, pharmaceutical compositions and therapeutic methods thereof
WO2024220874A2 (en) Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs)
CN118354999A (zh) 一种哒嗪-1(6h)-6-氧代类化合物及其制备方法与应用
WO2023119098A1 (en) Protein kinase c theta inhibitors
JP2023550609A (ja) 貧血の処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシピロリジン－２－カルボキサミド誘導体
CN116903626A (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260130